Compare Global X Autonomous & Electric Vehicles (DRIV) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Gilead Sciences, Inc. — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.8 (market cap $356.37M), while Gilead Sciences, Inc. trades at $148.22 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 511.8× Global X Autonomous & Electric Vehicles's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Gilead Sciences, Inc. for 111 Days on average.
| DRIV | GILD | |
|---|---|---|
Market Cap | $356.37M | $182.40B |
Volume | 22,397 | 4,469,821 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $155.80 |
52-Week Low | $27.58 | $116.74 |
Typical Hold Time | 40 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $33.37, down 1.68% today amid mixed technical signals. The overall technical outlook is bullish with neutral oscillators, while key support sits at $33. Recent news highlights automotive sector focus on hybrid and electric vehicles, though company-specific financial ratios are currently unavailable for analysis.
The stock shows technical resilience near support levels with bullish momentum indicators. Investment appeal hinges on forthcoming financial disclosures and sector trends favoring EV/hybrid adoption. Key risks include sector competition and reliance on broader automotive market performance without current fundamental data.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
